Diabetes

The drug is the first rapid-acting insulin biosimilar product approved for use by the FDA, marking a significant milestone in diabetes treatment.

Recently, there has been concern around glucagon-like peptide-1 receptor agonists and increase the risk of thyroid cancer, with liraglutide having a black box warning label for the disease.

Social media can help close the gap on health care information access, but pharmacists still play a large role in diabetes management, especially in therapeutics.

App notifications can be effected by various notification focuses, software updates, or connecting hardware, such as car audio or wireless earphones.

Children with type 1 diabetes who watched educational videos and played games had improved glycemic control and quality of life.

The therapy is now the first and only FDA-approved treatment that maintains vision with fewer treatments compared to standard-of-care injections.

Sodium-glucose cotransporter 2 inhibitors are more cardioprotective in older adults and glucagon-like peptide-1 receptor agonists for younger patients.

There is no standard way to define resilience in adolescent patients with type 1 diabetes, though many studies see resilience as an ability or process.

Patients with diabetes and prediabetes have older brain ages than their chronological age compared with normoglycemic patients.

A recent systematic review and meta-analysis found that almost half of all patients with type 2 diabetes were deficient in multiple micronutrients.

Ozempic is now the most broadly indicated glucagon-like peptide-1 receptor agonist across the pharmaceutical drug market.

Among a population of patients with type 2 diabetes, researchers assessed the similarities and differences between SGLT2 inhibitors.

Heather Folz, PharmD, BCACP and Christina H. Sherrill, PharmD, BCACP, BC-ADM discuss challenges pharmacists may face when implementing CGM services and how they can help raise awareness.

Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed current GLP-1 medication offerings and how each impacts patients differently.

Investigators of a recent study said targeted interventions are needed to reduce the global burden, particularly in developing countries.

Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed the benefits of tirzepatide compared with semaglutide.

A study found that sending a letter to providers about standards of care and glucagon preparations could increase glucagon prescription rates.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses the benefits of glucagon and why pharmacists should be able to prescribe it.

Check out this list of our top 5 most read diabetes stories from the year 2024.

A conversation with Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, professor of pharmacy practice at Massachusetts College of Pharmacy and Health Sciences.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses key risk factors for hypoglycemia and what education programs should emphasize so people with diabetes and their caregivers can improve its management.

MannKind announced results from the INHALE-1 study that examined Afrezza in children and adolescents with diabetes.

Student pharmacists who wore a continuous glucose monitor had a higher average counseling score during an encounter with a patient and a higher overall confidence score.

Two posters presented at the meeting looked into the topic CGMs in diabetes care.

Denise Kelley, PharmD, BCPS, FASHP, joined Drug Topics to discuss various medications for chronic kidney disease and their common adverse reactions.

Research found that SGLT2 inhibitors were associated with a lower risk of major cardiovascular events or hospitalization for heart failure.

Denise Kelley, PharmD, BCPS, FASHP, discussed the efficacy of medications designed to treat the progression of chronic kidney disease.

Medication alerts, nurse education, and pharmacist interventions led to lower hypoglycemic events every year after they were implemented.

Research also showed that the percentage of no-show appointments was slightly higher in a pre-virtual group compared to a post-virtual group.

Efficacy data for dapagliflozin and empagliflozin in a group of Asian patients were evaluated.